Skip to main content

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

  • The original article was published in The Journal of Headache and Pain 2019 20:75

Correction to: J Headache Pain

https://doi.org/10.1186/s10194-019-1024-x

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.

Fig. 7
figure1

The overall least-squares (LS) mean change in Migraine Disability Assessment (MIDAS) total Score for the average of Months 3 and 6 is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The LS mean changes in MIDAS total score at Months 3 and 6 for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. ***p ≤ .001, **p ≤ .01, *p ≤ .05 vs placebo

Reference

  1. 1.

    Silberstein et al (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20:75. https://doi.org/10.1186/s10194-019-1024-x

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stephen D. Silberstein.

Additional information

The original article can be found online at https://doi.org/10.1186/s10194-019-1024-x

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Silberstein, S.D., Stauffer, V.L., Day, K.A. et al. Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20, 118 (2019). https://doi.org/10.1186/s10194-019-1069-x

Download citation